Allegro’s Vicken Karageozian, MD, talks about the risuteganib phase 2 for intermediate dry AMD (showing a “robust reversal of vision loss”), their dry eye drug program, and transitioning into business from medicine.
Watch Vicken Karageozian, MD, President & CEO, Allegro interview with OIS TV during OIS@AAO 2019 in San Francisco.
REGISTER for our next ophthalmology conference today.
STAY UP TO DATE WITH OIS
Get the Latest News, Podcasts and Videos.